Skip to content

Study · Non-randomized trial · n = 30 · 1997

11 results

Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years.

Wallymahmed ME, Foy P, Shaw D, Hutcheon R, Edwards RH, MacFarlane IA

Clinical endocrinology1 Oct 1997Cited by 73 (Europe PMC)

PMID9404442 (opens in a new tab)DOI10.1046/j.1365-2265.1997.2801076.x (opens in a new tab)PepBankPUB-09404442
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, lean mass increased significantly in both groups after 6-12 months of GH.

    In plain wordsIn GH-deficient adults, lean mass increased in both groups after 6-12 months of GH.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean mass
    Study

    n = 30

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months of each study period · injections · 6-12 monthsAs given in this study (human).

    Source sentences

    Summary
    Body composition altered favourably over the initial 12-month study period with a significant increase in lean mass and decrease in fat mass in both groups after 6-12 months of GH.
    1 context sentence
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  2. 02HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, fat mass decreased significantly in both groups after 6-12 months of GH.

    In plain wordsIn GH-deficient adults, fat mass decreased in both groups after 6-12 months of GH.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseFat mass
    Study

    n = 30

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months of each study period · injections · 6-12 monthsAs given in this study (human).

    Source sentences

    Summary
    Body composition altered favourably over the initial 12-month study period with a significant increase in lean mass and decrease in fat mass in both groups after 6-12 months of GH.
    1 context sentence
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  3. 03HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, muscle strength did not change in either group during the initial 12-month study.

    In plain wordsIn GH-deficient adults, muscle strength did not change in either group during the initial 12-month study.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeMuscle strength during initial study
    Study

    n = 30

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months of each study period · injections · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no changes in muscle strength in either group during the initial 12-month study.
    1 context sentence
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults continuing GH, energy improved at 2 years versus baseline (P < 0.01).

    In plain wordsIn GH-deficient adults continuing GH, energy improved at 2 years versus baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseEnergy at two years
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · injections · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    In the patients who persisted with GH replacement, energy levels continued to improve (at 2 years, P < 0.01 compared with baseline) but then fell (at 3 years, P = NS compared with baseline).
    2 context sentences
    Summary · context
    Of these, 13 patients were available for assessment after a further 12 months' and 24 months' treatment.
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  5. 05HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults continuing GH, energy fell at 3 years and did not differ significantly from baseline.

    In plain wordsIn GH-deficient adults continuing GH, energy at 3 years did not differ significantly from baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeEnergy at three years
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · injections · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    In the patients who persisted with GH replacement, energy levels continued to improve (at 2 years, P < 0.01 compared with baseline) but then fell (at 3 years, P = NS compared with baseline).
    2 context sentences
    Summary · context
    Of these, 13 patients were available for assessment after a further 12 months' and 24 months' treatment.
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  6. 06HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults continuing GH, emotional reaction scores followed the energy pattern of improvement followed by decline.

    In plain wordsIn GH-deficient adults continuing GH, emotional reaction scores improved and then declined, similar to energy scores.

    Peptide
    HGH (somatotropin)
    Outcome
    MixedEmotional reaction score
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · injections · up to 3 yearsAs given in this study (human).

    Source sentences

    Summary
    A similar pattern was observed in emotional reaction scores.
    2 context sentences
    Summary · context
    In the patients who persisted with GH replacement, energy levels continued to improve (at 2 years, P < 0.01 compared with baseline) but then fell (at 3 years, P = NS compared with baseline).
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  7. 07HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults continuing GH, self-esteem improvement persisted at 3 years versus baseline (P < 0.05).

    In plain wordsIn GH-deficient adults continuing GH, self-esteem remained better at 3 years versus baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseSelf-esteem
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · injections · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    However, improvements in self-esteem were maintained (at 3 years, P < 0.05 compared with baseline).
    2 context sentences
    Summary · context
    Of these, 13 patients were available for assessment after a further 12 months' and 24 months' treatment.
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  8. 08HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults assessed after a further 12 months of GH, muscle strength increased versus baseline (P < 0.02).

    In plain wordsIn GH-deficient adults assessed after extended GH treatment, muscle strength increased versus baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseMuscle strength during extended treatment
    Study

    n = 13

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · injections · a further 12 monthsAs given in this study (human).

    Source sentences

    Summary
    However, in the patients who were available for assessment after a further 12 months of GH treatment, muscle strength increased significantly (P < 0.02 compared with baseline).
    2 context sentences
    Summary · context
    Of these, 13 patients were available for assessment after a further 12 months' and 24 months' treatment.
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  9. 09HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults treated for the full year, perceived energy increased after 6 and 12 months versus baseline (P < 0.01).

    In plain wordsIn GH-deficient adults treated for the full year, energy improved after 6 and 12 months versus baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePerceived energy
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months of each study period · injections · 6 and 12 monthsAs given in this study (human).

    Source sentences

    Summary
    In the initial 12 months' placebo-controlled study perceived energy levels increased after 6 and 12 months of GH treatment (P < 0.01 compared with baseline) in the patients receiving GH for the full 12-month period.
    1 context sentence
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  10. 10HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, impact scores improved slightly after 6 months of GH treatment (P < 0.05).

    In plain wordsIn GH-deficient adults, impact scores improved slightly after 6 months of GH compared with baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    Direction not reportedImpact score
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months of each study period · injections · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Also small improvements in impact scores were found after 6 months of GH treatment (P < 0.05) but this was not sustained at 12 months.
    1 context sentence
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).
  11. 11HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, the impact score improvement with GH was not sustained at 12 months.

    In plain wordsIn GH-deficient adults, the impact score improvement with GH did not persist at 12 months.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeSustained impact score improvement
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months of each study period · injections · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Also small improvements in impact scores were found after 6 months of GH treatment (P < 0.05) but this was not sustained at 12 months.
    1 context sentence
    Summary · context
    Thirty of the 32 adult patients with GH deficiency enrolled completed the initial 12-month study (10 male, mean age 33.5 years, mean (SD) stimulated serum GH response 3.0 mU/l (2.86)).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.